Related Experiment Video
Updated: Jun 11, 2025

Cholesterol Efflux Assay
Published on: March 6, 2012
Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
Daniel Elías-López1,2,3, Benjamin Nilsson Wadström1,2,4, Signe Vedel-Krogh1,2,4
1Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls Vej 1, 2730, Herlev, Denmark.
Insights
Elevated remnant cholesterol significantly increases atherosclerotic cardiovascular disease (ASCVD) risk in individuals with diabetes. Therapies targeting remnant cholesterol should also reduce apolipoprotein B (apoB) for effective ASCVD prevention.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Research
Background:
- Diabetes mellitus elevates atherosclerotic cardiovascular disease (ASCVD) risk, partly via hyperlipidemia.
- Residual ASCVD risk persists despite LDL cholesterol reduction, potentially linked to elevated remnant cholesterol.
Purpose of the Study:
- To elucidate the impact of elevated remnant cholesterol on ASCVD risk in diabetic patients.
- To review the role of remnant cholesterol as a therapeutic target in diabetes.
Main Methods:
- Review of preclinical, observational, and Mendelian randomization studies.
- Analysis of recent clinical trial data on remnant cholesterol-lowering therapies.
Main Results:
- Strong evidence suggests remnant cholesterol causally increases ASCVD risk.
- Clinical trials of omega-3 fatty acids and fibrates show conflicting ASCVD prevention results.
- Therapeutic strategies should aim to lower both remnant cholesterol and apolipoprotein B (apoB).
Conclusions:
- Elevated remnant cholesterol is a probable driver of ASCVD in diabetes.
- Effective remnant cholesterol-lowering therapies must also reduce apoB levels to mitigate ASCVD risk.
Purpose Of Review:
Individuals with diabetes face increased risk of atherosclerotic cardiovascular disease (ASCVD), in part due to hyperlipidemia. Even after LDL cholesterol-lowering, residual ASCVD risk persists, part of which may be attributed to elevated remnant cholesterol. We describe the impact of elevated remnant cholesterol on ASCVD risk in diabetes.
Recent Findings:
Preclinical, observational, and Mendelian randomization studies robustly suggest that elevated remnant cholesterol causally increases risk of ASCVD, suggesting remnant cholesterol could be a treatment target. However, the results of recent clinical trials of omega-3 fatty acids and fibrates, which lower levels of remnant cholesterol in individuals with diabetes, are conflicting in terms of ASCVD prevention. This is likely partly due to neutral effects of these drugs on the total level of apolipoprotein B(apoB)-containing lipoproteins. Elevated remnant cholesterol remains a likely cause of ASCVD in diabetes. Remnant cholesterol-lowering therapies should also lower apoB levels to reduce risk of ASCVD.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease I: Introduction
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Coronary Artery Disease IV: Medical Management